Table 3 galectin-1 expression in cancer cells and cancer-associated stromal cells along various pathologic characteristics

FIGO stage

CAS ^a

I

15 (76.0 %)

5 (24.0 %)

20

0.020

II

12 (43.0 %)

17 (57.0 %)

29

III

12 (32.0 %)

25 (68.0 %)

37

IV

3 (12.4 %)

21 (87.6 %)

24

EOC ^b cells

I

7 (36.5 %)

13 (63.5 %)

20

0.478

II

4 (14.4 %)

25 (85.6 %)

29

III

8 (21.5 %)

29 (78.5 %)

37

IV

8 (35.5 %)

16 (64.5 %)

24

Lymph

CAS ^a

node metastasis

Metastasis (−)

32 (48.2 %)

35 (51.8 %)

67

0.041

Metastasis (+)

12 (28.5 %)

31 (71.5 %)

43

EOC ^b cells

Metastasis (−)

14 (21.6 %)

53 (78.4 %)

67

0.214

Metastasis (+)

14 (32.8 %)

29 (67.2 %)

43

Recurrence

CAS ^a

Recurrence (−)

46 (77.3 %)

14 (22.7 %)

60

0.002

Recurrence (+)

15 (30.8 %)

35 (69.2 %)

50

EOC ^b cells

Recurrence (−)

24 (39.5 %)

36 (60.5 %)

60

0.245

Recurrence (+)

13 (25.6 %)

37 (74.4 %)

50